NCT01430559

Effect Of Meloxicam Versus Placebo In Mainland Chinese Patients With Osteoarthritis Of The Knee

A DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER, PARALLEL GROUP STUDY OF THE EFFECT OF MELOXICAM IN MAINLAND CHINESE SUBJECTS WITH OSTEOARTHRITIS (OA) OF THE KNEE

• Status: Completed
• Phase: N/A
• Study type: Interventional
• Enrollment: 408 (actual)
• Sponsor: Pfizer · Industry
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Accepted

Summary

This study is to validate the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) tool in mainland Chinese patients with osteoarthritis of the knee . This study will also evaluate the effects of Mobic versus placebo on reducing the symptoms of osteoarthritis in this population.

Detailed description

To validate culturally the WOMAC tool in mainland China and observe the different response of meloxicam and placebo in a patient population with osteoarthritis of the knee

Conditions

• Osteoarthritis of the Knee

Interventions

Type	Name	Description
DRUG	Meloxicam	7.5mg x2 once a day for 12 weeks
DRUG	Placebo	Study subjects will be randomized to two treatment groups: one with Meloxicam 7.5 mgx2 once a day and another one with placebo. The duration of the interventional treatment is 12 weeks.

Timeline

• Start date: 2011-10-24
• Primary completion: 2013-03-27
• Completion: 2013-03-27
• First posted: 2011-09-08
• Last updated: 2020-12-31
• Results posted: 2020-12-31

Locations

25 sites across 1 country: China